Videos

A new study explores strategies to enhance survival rates for patients facing challenges in finding bone marrow donors, advocating for quicker alternative options.

Discover key advancements in breast cancer treatment and the ongoing challenges in access, drug resistance, and patient quality of life.

Experts emphasize the need for regulatory alignment between the FDA and EMA to streamline radiopharmaceutical development and enhance patient access.

Lowell B. Anthony, MD, discusses the potential benefits of cabozantinib for patients for different types of patients with neuroendocrine tumors.

Discover groundbreaking advancements in breast cancer treatment, focusing on targeted therapies, immunotherapy, and personalized care strategies for improved patient outcomes.

Dr. Shane Dormady shares innovative cancer treatment strategies, emphasizing hope and precision medicine to empower young adult patients facing diagnoses.

Sarah Premji, MD, discusses recent advancements in the breast cancer treatment landscape.

Julie Brahmer, MD, and David P. Carbone, MD, PhD, share insights on managing toxicities of immune checkpoint inhibitor therapies in non–small cell lung cancer.

Dr Harpreet Singh discusses the FDA's new guidance on radiopharmaceutical dosing, emphasizing dose justification and data integration for patient safety.

Dr Harpreet Singh discusses the FDA's draft guidance on radiopharmaceutical dosing, highlighting significant shifts in dose limits and safety monitoring for clinical trials.

An expert discusses how moving lurbinectedin to earlier in treatment is justified because 40% to 50% of patients with small cell lung cancer (SCLC) never receive second-line therapy due to rapid disease progression, making proactive treatment essential.

An expert discusses efforts to improve the tolerability and delivery of the MARIPOSA regimen, highlighting subcutaneous amivantamab from the Paloma studies and proactive skin care strategies from the Cocoon study as key advances in enhancing patient experience, adherence, and clinical outcomes.

An expert discusses how lurbinectedin maintenance therapy causes primarily hematologic toxicities but has a low discontinuation rate (6.2%), making it suitable for most patients with good performance status and adequate blood count recovery.

Harpreet Singh, MD, former FDA director, discusses the FDA's new draft guidance on radiopharmaceutical dosing and its relation to Project Optimus.

Dr. Gerrina Ruiter discusses zongertinib's promising efficacy in treating HER2-mutant NSCLC, highlighting its unique effectiveness against brain metastases.

Innovative advancements in cell therapy enhance NK cells for solid tumors, aiming for effective treatments while prioritizing patient safety and clinical success.

Chandler H. Park, MD, discusses NCCN treatment regimens for patients with metastatic bladder cancer.

Discover how El Camino Health's multidisciplinary approach enhances cancer care for younger adults, featuring collaboration among diverse medical specialists.

Gerrina Ruiter, MD, PhD, highlights the Beamion LUNG-1 study's impact on treating HER2-mutant non-small cell lung cancer with brain metastases.

Katy Rezvani, MD, PhD, discusses advancements in CAR-NK cell therapy, focusing on enhancing antitumor efficacy while ensuring safety through precise gene editing techniques.

Dr Katy Rezvani reveals groundbreaking insights on enhancing CAR-NK cell therapy's effectiveness against solid tumors through innovative genetic strategies.

Katy Rezvani, MD, PhD, explores innovative CAR-NK cell therapies, highlighting their potential to overcome challenges in treating solid tumors and enhancing cancer treatment efficacy.

Andrew M. Brunner, MD, discusses the mechanism of action of telomerase inhibitors as treatment for anemia related to myelodysplastic syndrome.

Early-stage squamous cell carcinoma of the esophagus is primarily treated with endoscopic resection, while esophagectomy or chemoradiotherapy may be considered for select patients based on staging and overall health.

Shane Dormady, MD, discusses the unique emotional care needs of young adults with cancer, emphasizing hope and holistic support for better outcomes.

An expert discusses how the IMforte trial demonstrated that adding lurbinectedin to maintenance atezolizumab significantly improved progression-free survival (2.1 to 5.4 months) and overall survival (10.6 to 13.2 months) with an HR of 0.73.

An expert discusses how the IMpower133 trial established atezolizumab plus chemotherapy as standard care for extensive-stage small cell lung cancer (ES-SCLC), improving overall survival from 10.3 to 12.3 months, though most patients still don't achieve long-term survival.

An expert discusses the MARIPOSA study’s impact on managing central nervous system (CNS) involvement in EGFR-mutated non–small cell lung cancer, emphasizing improved brain progression-free survival, dual-targeted resistance prevention, and a promising shift toward more effective and personalized treatment strategies.

Discover how zipalertinib, an oral TKI, addresses unmet needs in treating EGFR exon 20 insertion-mutated non-small cell lung cancer.

Experts explore innovative therapies for high-risk smoldering multiple myeloma, aiming to delay progression and enhance patient outcomes through early intervention.